Genmab — Januar 2016
-
Johnson & Johnson (JNJ) Alex Gorsky on Q4 2015 Results - Earnings Call Transcript - http://seekingalpha.com/article/3835816-johnson-and-johnson-jnj-alex-gorsky-q4-2015-results-earnings-call-transcript
-
I would first like to address our cash position and remind you about our capital allocation approach. At the end of the quarter we had approximately $18.5 billion of net cash, which consists of approximately $38.5 billion of cash and marketable securities and approximately $20 billion of debt. This is a higher level of cash than we typically hold. And as Alex said earlier, we are actively looking for the right opportunities to deploy that capital to create greater value for our shareholders.
-
Yeah, Glenn, look, we're fortunate in that because of our strong performance, our strong cash flows, that our balance sheet is actually quite strong. I also believe that if you look at our track record of how we've utilized that cash to make the right capital investments in companies, that we've been successful with that. And look, we think that there's opportunities across all three of our different sectors.
-
And it's not an algorithm per se, as we decide which and where to invest, but rather it really depends on the opportunity. And many of the factors that Dominic described earlier, as far as what are the specific platforms that we're looking at? Where is the partner in terms of their decision making, what they want to do with the business? And frankly what the competitive environment is like?
-
-
Besparelser og store opkøb på dagsordenen hos J&J
Den store life science-koncern Johnson & Johnson beroliger markedet med omfattende besparelser, der skal sikre indtjeningen, og melder samtidig om en trecifret milliardsum i kontanter, som man gerne vil bruge.
(medwatch.dk)
-
Spændende, men så længe JDW sidder på magten og har opbakning i "iglerbestyrelsen" som tjener gode penge uden at yde en skid så bliver butikken ikke solgt. Iglerne vil jo ikke miste deres fine indtægt. Måske vi skulle kræve biksen solgt til næste generelforsamling for rette pris, hvilket dog ikke vil være en fordel for aktionærer med lang tidshorisont.
-
vi ligger lidt efter de andre pharma'er i DK - mon ikke det er en udenlandsk investor, der reducerer langsomt. GEN plejer jo at kunne følge med de andre uden besvær
-
det kunne evt være på baggrund af at JJ og Novartis nu har været ude med Q4, og der ikke var nogle nyheder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind